Report Thumbnail
Product Code QY0912715488P37
Published Date 2024/7/2
QY Research
English129 PagesGlobal

Global Duchenne Muscular Dystrophy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code QY0912715488P37◆The Jul 2025 edition is also likely available. We will check with the publisher immediately.
Published Date 2024/7/2
QY Research
English 129 PagesGlobal

Global Duchenne Muscular Dystrophy Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030 ‐ Pharmaceutical_LifeSciense Market


Abstract

Summary

uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
The global Duchenne Muscular Dystrophy market is projected to reach US$ 13540 million by 2030 from an estimated US$ 1644 million in 2024, at a CAGR of 42.1% during 2024 and 2030.
Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.
North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.
In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy.
The Duchenne Muscular Dystrophy market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Duchenne Muscular Dystrophy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application, and regions.
Market Segmentation
By Company
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Segment by Type
Exondys 51
Emflaza
Translarna
Segment by Application
Hospitals
Clinics
Home Care
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Duchenne Muscular Dystrophy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Duchenne Muscular Dystrophy sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.

Table of Contents

  • 1 Study Coverage

    • 1.1 Duchenne Muscular Dystrophy Product Introduction
    • 1.2 Market by Type
      • 1.2.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type (2019 VS 2023 VS 2030)
      • 1.2.2 Exondys 51
      • 1.2.3 Emflaza
      • 1.2.4 Translarna
    • 1.3 Market by Application
      • 1.3.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Application (2019 VS 2023 VS 2030)
      • 1.3.2 Hospitals
      • 1.3.3 Clinics
      • 1.3.4 Home Care
    • 1.4 Study Objectives
    • 1.5 Years Considered

  • 2 Executive Summary

    • 2.1 Global Duchenne Muscular Dystrophy Market Size Estimates and Forecasts
      • 2.1.1 Global Duchenne Muscular Dystrophy Revenue 2019-2030
      • 2.1.2 Global Duchenne Muscular Dystrophy Sales 2019-2030
    • 2.2 Duchenne Muscular Dystrophy Market Size by Region: 2023 Versus 2030
    • 2.3 Duchenne Muscular Dystrophy Sales by Region (2019-2030)
      • 2.3.1 Global Duchenne Muscular Dystrophy Sales by Region: 2019-2024
      • 2.3.2 Global Duchenne Muscular Dystrophy Sales Forecast by Region (2025-2030)
      • 2.3.3 Global Duchenne Muscular Dystrophy Sales Market Share by Region (2019-2030)
    • 2.4 Duchenne Muscular Dystrophy Market Estimates and Projections by Region (2025-2030)
      • 2.4.1 Global Duchenne Muscular Dystrophy Revenue by Region: 2019-2024
      • 2.4.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Region (2025-2030)
      • 2.4.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2019-2030)

  • 3 Global Duchenne Muscular Dystrophy by Manufacturers

    • 3.1 Global Top Duchenne Muscular Dystrophy Manufacturers by Sales
      • 3.1.1 Global Duchenne Muscular Dystrophy Sales by Manufacturer (2019-2024)
      • 3.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturer (2019-2024)
    • 3.2 Global Top Duchenne Muscular Dystrophy Manufacturers by Revenue
      • 3.2.1 Global Duchenne Muscular Dystrophy Revenue by Manufacturer (2019-2024)
      • 3.2.2 Global Duchenne Muscular Dystrophy Revenue Share by Manufacturer (2019-2024)
    • 3.3 Global Duchenne Muscular Dystrophy Price by Manufacturer (2019-2024)
    • 3.4 Competitive Landscape
      • 3.4.1 Key Duchenne Muscular Dystrophy Manufacturers Covered: Ranking by Revenue
      • 3.4.2 Global Duchenne Muscular Dystrophy Market Concentration Ratio (CR5 and HHI) & (2019-2024)
      • 3.4.3 Global Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 3.5 Global Duchenne Muscular Dystrophy Manufacturing Base Distribution, Product Type
      • 3.5.1 Duchenne Muscular Dystrophy Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.5.2 Manufacturers Duchenne Muscular Dystrophy Product Type
      • 3.5.3 Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Market
    • 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

  • 4 Company Profiles

    • 4.1 Sarepta Therapeutics
      • 4.1.1 Sarepta Therapeutics Company Information
      • 4.1.2 Sarepta Therapeutics Description, Business Overview
      • 4.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Products Offered
      • 4.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
      • 4.1.5 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales by Product in 2023
      • 4.1.6 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales by Application in 2023
      • 4.1.7 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales by Geographic Area in 2023
      • 4.1.8 Sarepta Therapeutics Recent Developments
    • 4.2 PTC Therapeutics
      • 4.2.1 PTC Therapeutics Company Information
      • 4.2.2 PTC Therapeutics Description, Business Overview
      • 4.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Products Offered
      • 4.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
      • 4.2.5 PTC Therapeutics Duchenne Muscular Dystrophy Sales by Product in 2023
      • 4.2.6 PTC Therapeutics Duchenne Muscular Dystrophy Sales by Application in 2023
      • 4.2.7 PTC Therapeutics Duchenne Muscular Dystrophy Sales by Geographic Area in 2023
      • 4.2.8 PTC Therapeutics Recent Developments
    • 4.3 Pfizer
      • 4.3.1 Pfizer Company Information
      • 4.3.2 Pfizer Description, Business Overview
      • 4.3.3 Pfizer Duchenne Muscular Dystrophy Products Offered
      • 4.3.4 Pfizer Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
      • 4.3.5 Pfizer Duchenne Muscular Dystrophy Sales by Product in 2023
      • 4.3.6 Pfizer Duchenne Muscular Dystrophy Sales by Application in 2023
      • 4.3.7 Pfizer Duchenne Muscular Dystrophy Sales by Geographic Area in 2023
      • 4.3.8 Pfizer Recent Developments
    • 4.4 Bristol-Myers Squibb
      • 4.4.1 Bristol-Myers Squibb Company Information
      • 4.4.2 Bristol-Myers Squibb Description, Business Overview
      • 4.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Products Offered
      • 4.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
      • 4.4.5 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales by Product in 2023
      • 4.4.6 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales by Application in 2023
      • 4.4.7 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales by Geographic Area in 2023
      • 4.4.8 Bristol-Myers Squibb Recent Developments
    • 4.5 Italfarmaco
      • 4.5.1 Italfarmaco Company Information
      • 4.5.2 Italfarmaco Description, Business Overview
      • 4.5.3 Italfarmaco Duchenne Muscular Dystrophy Products Offered
      • 4.5.4 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
      • 4.5.5 Italfarmaco Duchenne Muscular Dystrophy Sales by Product in 2023
      • 4.5.6 Italfarmaco Duchenne Muscular Dystrophy Sales by Application in 2023
      • 4.5.7 Italfarmaco Duchenne Muscular Dystrophy Sales by Geographic Area in 2023
      • 4.5.8 Italfarmaco Recent Developments
    • 4.6 Santhera Pharmaceuticals
      • 4.6.1 Santhera Pharmaceuticals Company Information
      • 4.6.2 Santhera Pharmaceuticals Description, Business Overview
      • 4.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Products Offered
      • 4.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
      • 4.6.5 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales by Product in 2023
      • 4.6.6 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales by Application in 2023
      • 4.6.7 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales by Geographic Area in 2023
      • 4.6.8 Santhera Pharmaceuticals Recent Development

  • 5 Breakdown Data by Type

    • 5.1 Global Duchenne Muscular Dystrophy Sales by Type (2019-2030)
      • 5.1.1 Global Duchenne Muscular Dystrophy Sales by Type (2019-2024)
      • 5.1.2 Global Duchenne Muscular Dystrophy Sales Forecast by Type (2025-2030)
      • 5.1.3 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2019-2030)
    • 5.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Type (2019-2030)
      • 5.2.1 Global Duchenne Muscular Dystrophy Revenue by Type (2019-2024)
      • 5.2.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Type (2025-2030)
      • 5.2.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2019-2030)
    • 5.3 Duchenne Muscular Dystrophy Average Selling Price (ASP) by Type (2019-2030)

  • 6 Breakdown Data by Application

    • 6.1 Global Duchenne Muscular Dystrophy Sales by Application (2019-2030)
      • 6.1.1 Global Duchenne Muscular Dystrophy Sales by Application (2019-2024)
      • 6.1.2 Global Duchenne Muscular Dystrophy Sales Forecast by Application (2025-2030)
      • 6.1.3 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2019-2030)
    • 6.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Application (2019-2030)
      • 6.2.1 Global Duchenne Muscular Dystrophy Revenue by Application (2019-2024)
      • 6.2.2 Global Duchenne Muscular Dystrophy Revenue Forecast by Application (2025-2030)
      • 6.2.3 Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2019-2030)
    • 6.3 Duchenne Muscular Dystrophy Average Selling Price (ASP) by Application (2019-2030)

  • 7 North America

    • 7.1 North America Duchenne Muscular Dystrophy Market Size YoY Growth 2019-2030
    • 7.2 North America Duchenne Muscular Dystrophy Market Facts & Figures by Country
      • 7.2.1 North America Duchenne Muscular Dystrophy Sales by Country (2019-2030)
      • 7.2.2 North America Duchenne Muscular Dystrophy Revenue by Country (2019-2030)
    • 7.3 North America Duchenne Muscular Dystrophy Sales by Type (2019-2024)
    • 7.4 North America Duchenne Muscular Dystrophy Sales by Application (2019-2024)

  • 8 Asia-Pacific

    • 8.1 Asia-Pacific Duchenne Muscular Dystrophy Market Size YoY Growth 2019-2030
    • 8.2 Asia-Pacific Duchenne Muscular Dystrophy Market Facts & Figures by Region
      • 8.2.1 Asia-Pacific Duchenne Muscular Dystrophy Sales by Region (2019-2030)
      • 8.2.2 Asia-Pacific Duchenne Muscular Dystrophy Revenue by Region (2019-2030)
    • 8.3 Asia-Pacific Duchenne Muscular Dystrophy Sales by Type (2019-2024)
    • 8.4 Asia-Pacific Duchenne Muscular Dystrophy Sales by Application (2019-2024)

  • 9 Europe

    • 9.1 Europe Duchenne Muscular Dystrophy Market Size YoY Growth 2019-2030
    • 9.2 Europe Duchenne Muscular Dystrophy Market Facts & Figures by Country
      • 9.2.1 Europe Duchenne Muscular Dystrophy Sales by Country (2019-2030)
      • 9.2.2 Europe Duchenne Muscular Dystrophy Revenue by Country (2019-2030)
    • 9.3 Europe Duchenne Muscular Dystrophy Sales by Type (2019-2024)
    • 9.4 Europe Duchenne Muscular Dystrophy Sales by Application (2019-2024)

  • 10 Latin America

    • 10.1 Latin America Duchenne Muscular Dystrophy Market Size YoY Growth 2019-2030
    • 10.2 Latin America Duchenne Muscular Dystrophy Market Facts & Figures by Country
      • 10.2.1 Latin America Duchenne Muscular Dystrophy Sales by Country (2019-2030)
      • 10.2.2 Latin America Duchenne Muscular Dystrophy Revenue by Country (2019-2030)
    • 10.3 Latin America Duchenne Muscular Dystrophy Sales by Type (2019-2024)
    • 10.4 Latin America Duchenne Muscular Dystrophy Sales by Application (2019-2024)

  • 11 Middle East and Africa

    • 11.1 Middle East and Africa Duchenne Muscular Dystrophy Market Size YoY Growth 2019-2030
    • 11.2 Middle East and Africa Duchenne Muscular Dystrophy Market Facts & Figures by Country
      • 11.2.1 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2019-2030)
      • 11.2.2 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2019-2030)
    • 11.3 Middle East and Africa Duchenne Muscular Dystrophy Sales by Type (2019-2024)
    • 11.4 Middle East and Africa Duchenne Muscular Dystrophy Sales by Application (2019-2024)

  • 12 Supply Chain and Sales Channel Analysis

    • 12.1 Duchenne Muscular Dystrophy Supply Chain Analysis
    • 12.2 Duchenne Muscular Dystrophy Key Raw Materials and Upstream Suppliers
    • 12.3 Duchenne Muscular Dystrophy Clients Analysis
    • 12.4 Duchenne Muscular Dystrophy Sales Channel and Sales Model Analysis
      • 12.4.1 Duchenne Muscular Dystrophy Distribution Channel Analysis: Indirect Sales VS Direct Sales
      • 12.4.2 Duchenne Muscular Dystrophy Distribution Channel Analysis: Online Sales VS Offline Sales
      • 12.4.3 Duchenne Muscular Dystrophy Distributors

  • 13 Market Dynamics

    • 13.1 Duchenne Muscular Dystrophy Industry Trends
    • 13.2 Duchenne Muscular Dystrophy Market Drivers
    • 13.3 Duchenne Muscular Dystrophy Market Challenges
    • 13.4 Duchenne Muscular Dystrophy Market Restraints

  • 14 Research Findings and Conclusion

  • 15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Author Details
    • 15.3 Disclaimer
USD 5,900 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.